280 related articles for article (PubMed ID: 11124893)
1. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.
Knott C; Stern G; Wilkin GP
Mol Cell Neurosci; 2000 Dec; 16(6):724-39. PubMed ID: 11124893
[TBL] [Abstract][Full Text] [Related]
2. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
3. Neuroinflammatory processes in Parkinson's disease.
Hunot S; Hirsch EC
Ann Neurol; 2003; 53 Suppl 3():S49-58; discussion S58-60. PubMed ID: 12666098
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration.
Arimoto T; Bing G
Neurobiol Dis; 2003 Feb; 12(1):35-45. PubMed ID: 12609487
[TBL] [Abstract][Full Text] [Related]
5. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
Mogi M; Kondo T; Mizuno Y; Nagatsu T
Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
[TBL] [Abstract][Full Text] [Related]
6. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation.
Teismann P; Schulz JB
Cell Tissue Res; 2004 Oct; 318(1):149-61. PubMed ID: 15338271
[TBL] [Abstract][Full Text] [Related]
7. Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion.
Helkamaa T; Reenilä I; Tuominen RK; Soinila S; Väänänen A; Tilgmann C; Rauhala P
Neurochem Int; 2007; 51(6-7):412-23. PubMed ID: 17573159
[TBL] [Abstract][Full Text] [Related]
8. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
9. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
10. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
[TBL] [Abstract][Full Text] [Related]
11. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways.
Lee DY; Oh YJ; Jin BK
Glia; 2005 Aug; 51(2):98-110. PubMed ID: 15789435
[TBL] [Abstract][Full Text] [Related]
13. Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease.
Okuno T; Nakatsuji Y; Kumanogoh A; Moriya M; Ichinose H; Sumi H; Fujimura H; Kikutani H; Sakoda S
J Neurosci Res; 2005 Sep; 81(6):874-82. PubMed ID: 16041799
[TBL] [Abstract][Full Text] [Related]
14. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration.
Iravani MM; Kashefi K; Mander P; Rose S; Jenner P
Neuroscience; 2002; 110(1):49-58. PubMed ID: 11882372
[TBL] [Abstract][Full Text] [Related]
15. Role of inducible nitric oxide synthase in N-methyl-d-aspartic acid-induced strio-nigral degeneration.
Iravani MM; Liu L; Rose S; Jenner P
Brain Res; 2004 Dec; 1029(1):103-13. PubMed ID: 15533321
[TBL] [Abstract][Full Text] [Related]
16. Pathological dynamics of activated microglia following medial forebrain bundle transection.
Cho BP; Song DY; Sugama S; Shin DH; Shimizu Y; Kim SS; Kim YS; Joh TH
Glia; 2006 Jan; 53(1):92-102. PubMed ID: 16206155
[TBL] [Abstract][Full Text] [Related]
17. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats.
Cicchetti F; Lapointe N; Roberge-Tremblay A; Saint-Pierre M; Jimenez L; Ficke BW; Gross RE
Neurobiol Dis; 2005 Nov; 20(2):360-71. PubMed ID: 16242641
[TBL] [Abstract][Full Text] [Related]
18. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
20. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
